用于治疗肝病的新型17β-羟类固醇脱氢酶13（HSD17B13）抑制剂
Novel HSD17B13 Inhibitors for Treating Liver Diseases.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Suite 1000, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2024 May 16;15(6):771-772. doi: 10.1021/acsmedchemlett.4c00195. eCollection 2024 Jun 13.
Abstract
Provided herein are novel HSD17B13 inhibitors, pharmaceutical compositions, use of such compounds in treating liver diseases, and processes for preparing such compounds.
摘要
本文提供了新型17β-羟基类固醇脱氢酶13（HSD17B13）抑制剂、药物组合物、此类化合物在治疗肝脏疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel HSD17B13 Inhibitors for Treating Liver Diseases.用于治疗肝病的新型17β-羟类固醇脱氢酶13（HSD17B13）抑制剂
ACS Med Chem Lett. 2024 May 16;15(6):771-772. doi: 10.1021/acsmedchemlett.4c00195. eCollection 2024 Jun 13.
2
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.作为治疗心血管疾病的NLRP3抑制剂的新型化合物。
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
3
Novel Heterocyclic Compounds as Monoacylglycerol Lipase Inhibitors for Treating Multiple Diseases.作为用于治疗多种疾病的单酰甘油脂肪酶抑制剂的新型杂环化合物。
ACS Med Chem Lett. 2024 Jun 21;15(7):994-995. doi: 10.1021/acsmedchemlett.4c00261. eCollection 2024 Jul 11.
4
BI-3231, an enzymatic inhibitor of HSD17B13, reduces lipotoxic effects induced by palmitic acid in murine and human hepatocytes.BI-3231是一种HSD17B13的酶抑制剂，可降低棕榈酸在小鼠和人类肝细胞中诱导的脂毒性作用。
Am J Physiol Cell Physiol. 2024 Mar 1;326(3):C880-C892. doi: 10.1152/ajpcell.00413.2023. Epub 2024 Jan 15.
5
Novel Fused Triazole Compounds as RIPK1 Inhibitors for Treating Neurodegenerative, Autoimmune, and Inflammatory Diseases.新型稠合三唑化合物作为用于治疗神经退行性、自身免疫性和炎症性疾病的RIPK1抑制剂
ACS Med Chem Lett. 2024 Jan 26;15(2):177-178. doi: 10.1021/acsmedchemlett.4c00011. eCollection 2024 Feb 8.
6
Novel PCSK9 Inhibitors for Treating Cardiovascular Diseases.用于治疗心血管疾病的新型前蛋白转化酶枯草溶菌素9（PCSK9）抑制剂
ACS Med Chem Lett. 2024 Mar 8;15(4):443-444. doi: 10.1021/acsmedchemlett.4c00088. eCollection 2024 Apr 11.
7
Novel Heterocyclic PAD4 Inhibitors for Treating Diseases.用于治疗疾病的新型杂环PAD4抑制剂
ACS Med Chem Lett. 2024 Feb 27;15(3):340-341. doi: 10.1021/acsmedchemlett.4c00075. eCollection 2024 Mar 14.
8
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.新型三嗪类化合物作为治疗多种疾病的NLRP3抑制剂
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
9
Novel TYK2 Inhibitors for Treating Autoimmune and Inflammatory Diseases.用于治疗自身免疫性和炎性疾病的新型酪氨酸激酶2（TYK2）抑制剂
ACS Med Chem Lett. 2024 Dec 9;16(1):8-9. doi: 10.1021/acsmedchemlett.4c00566. eCollection 2025 Jan 9.
10
Novel Heterocyclic PAD4 Inhibitors for Treating Multiple Diseases.用于治疗多种疾病的新型杂环PAD4抑制剂。
ACS Med Chem Lett. 2024 Jan 23;15(2):179-180. doi: 10.1021/acsmedchemlett.4c00012. eCollection 2024 Feb 8.
本文引用的文献
1
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease.肝线粒体还原应激在脂肪性肝病发病机制和治疗中的作用。
Trends Pharmacol Sci. 2024 Apr;45(4):319-334. doi: 10.1016/j.tips.2024.02.003. Epub 2024 Mar 12.
2
Drug development advances in human genetics-based targets.基于人类遗传学靶点的药物研发进展。
MedComm (2020). 2024 Feb 9;5(2):e481. doi: 10.1002/mco2.481. eCollection 2024 Feb.
3
Novel insights into metabolic-associated steatotic liver disease preclinical models.代谢相关性脂肪性肝病临床前模型的新见解。
Liver Int. 2024 Mar;44(3):644-662. doi: 10.1111/liv.15830. Epub 2024 Jan 30.
4
Alcohol-associated liver disease: Epidemiology and management.酒精相关性肝病：流行病学和管理。
Ann Hepatol. 2024 Jan-Feb;29(1):101162. doi: 10.1016/j.aohep.2023.101162. Epub 2023 Oct 12.
5
Unraveling the pathogenesis of non-alcoholic fatty liver diseases through genome-wide association studies.通过全基因组关联研究揭示非酒精性脂肪性肝病的发病机制。
J Gastroenterol Hepatol. 2023 Nov;38(11):1877-1885. doi: 10.1111/jgh.16330. Epub 2023 Aug 17.
6
17β-hydroxysteroid dehydrogenases in the progression of nonalcoholic fatty liver disease.17β-羟甾类脱氢酶在非酒精性脂肪性肝病进展中的作用。
Pharmacol Ther. 2023 Jun;246:108428. doi: 10.1016/j.pharmthera.2023.108428. Epub 2023 Apr 26.
Zotero 插件